Development of an Integral Strategy for Model-based Dose Adaptation in Chemotherapy Year Two
Drug models describe the relationship between exposure (or pharmacokinetics), response (or pharmacodynamics) for both desired and undesired effects, and individual patient characteristics. In this project, drug models will be used to propose an integrated dose adaption strategy for cancer treatment. This strategy has a particular clinical value for our partner (InVentiv Health Clinical, a Contract Research Organization) because it would allow to better inform of the drug development process, thus reducing studies´ cost, drug development duration and risks in a long run. Furthermore, there is a potential benefit for cancer patients. An adequate dose adaption strategy would theoretically decrease its associated toxicities and therefore, the "quality of life" of the cancer patient might be deeply improved.